The Week in Review: Aug 31 – Sep 7, 2018

Friday, Sep 7, 2018 News Recap: London Drugs Launches Potentially Life-Saving Hepatitis C Screening at Pharmacies in BC Lower Mainland. An innovative and potentially life-saving hepatitis C screening program has launched at five London Drugs locations in the Lower Mainland. Patients can now undertake a simple finger prick test at the pharmacy to check if they have been exposed to hepatitis C virus (HCV) at some point in the past. Hundreds of pati...

Coffee, Pot Linked to Lower Mortality From Hepatitis C

Increased consumption of coffee and marijuana may sharply reduce the risk for early death from hepatitis C infection, researchers have found. The study of more than 1,200 patients with HCV and HIV found that those who drank the most coffee and used marijuana regularly or daily had more than a 60% lower risk for death from the infection over a five-year period. How cannabis in particular might reduce mortality is unclear, but the researchers, led by Mar

Patients with chronic HBV die at younger age

Patients with chronic hepatitis B virus infection died an average of 14 years younger and had higher incidences of death from all causes compared with the general U.S. population, according to study results recently published in Clinical Infectious Diseases. “In the United States, about 1,800 death certificates annually list hepatitis B virus (HBV) as an underlying or contributing cause of death,” researchers wrote. “However, accurately quantifying mortal

The Week in Review: February 23 – March 2, 2018

Friday, March 2, 2018 News Recap: Canada: Shifting from concern to crisis: 1 in 4 Canadians may be affected by liver disease. Recent indicators gathered by the Canadian Liver Foundation (CLF) show that an increased prevalence of liver diseases including non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B & C, and liver cancer are why in just ten years, the statistic that was once 1 in 10, is now 1 in 4. Ontario Expands Patient Acce...

DAA therapy improves HCV-related liver transplantation outcomes

The high efficacy of direct-acting antivirals correlated with significant improvement in survival of patients who underwent liver transplantation for hepatitis C-related liver disease, according to a recently published study. Hepatitis C virus (HCV) infection is the main cause of end-stage liver disease leading to liver transplantation (LT) in the Western world, and until the widespread use of the direct-acting antiviral regimens (DAA) it had a significan

Chronic Hepatitis B: Serum ALT Cutoff Value Predictive of Liver-Related Mortality

In patients with chronic hepatitis B, serum alanine aminotransferase (ALT) levels are positively correlated with liver-related mortality, according to study results published in Liver International. The researchers recommend that patients age >40 with serum ALT levels above the upper limit of normal should be carefully monitored or started on antiviral therapy earlier. Read more...https://www.infectiousdiseaseadvisor.com/hepatitis-advisor/predicting

The Week in Review: February 16 – February 23, 2018

Friday, February 23, 2018 News Recap: Way to Go, Ontario! Ontario removes fibrosis requirement for HCV treatment effective Feb 28th.  Action Hepatitis Canada has just shared some great news: Ontario has announced today that effective February 28, 2018, the fibrosis requirement for hepatitis C treatment will be removed! Finally, diagnosis of chronic hepatitis C and genotyping is all that will be required in Ontario to access treatment. This announcem...

Significant Mortality Benefit Seen With Sustained HCV Virologic Response With DAAs

For patients infected with hepatitis C virus(HCV) without advanced liver disease, achieving sustained virologic response with direct-acting antivirals (DAAs) is associated with decreased mortality, according to results published in Hepatology. The mortality rate of patients who achieved sustained virologic response was 1.18 deaths/100 patient years compared with 2.84 deaths/100 patient years for patients who did not achieve sustained virologic response, a

The Week in Review: January 26 – February 2, 2018

Friday, February 2, 2018 News Recap: From the Uh-Oh Department: HCV Can Reactivate with Treatment of Non-hepatic Cancer. Hepatitis C virus (HCV) reactivation occurred in approximately 1 out of 5 patients treated for non-hepatic cancer, posing renewed risk for hepatic injury and possibly complicating the cancer treatment. Compensation Update: Compensation – New Update for 86-90 Late Claims. If you or a family member received a blood transfusion o...

SVR for HCV with no advanced liver disease greatly reduces mortality risk

Patients with hepatitis C without advanced liver disease who achieved sustained virologic response with direct-acting antiviral therapy had significantly reduced all-cause mortality rates compared with both treated patients who did not achieve SVR and untreated patients, according to a recently published data. “These data strongly support a clinically significant benefit of DAA treatment in patients without clinically apparent advanced liver disease and e